pyrazines has been researched along with pd 184352 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bodie, WW; Chen, S; Dai, Y; Felthousen, J; Grant, S; Kramer, LB; Orlowski, RZ; Pei, XY; Sanderson, MW; Takabatake, Y; Youssefian, LE; Zhou, L | 1 |
1 other study(ies) available for pyrazines and pd 184352
| Article | Year |
|---|---|
Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Checkpoint Kinase 1; Cytoprotection; Down-Regulation; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Membrane Proteins; Mesenchymal Stem Cells; Mitogen-Activated Protein Kinase Kinases; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins; Pyrazines; Syndecan-1; Up-Regulation | 2014 |